Diagnosis and treatment of cancer related to human dormancy

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S667000, C424S094600, C514S343000, C514S474000, C536S008000, C536S016800, C436S500000

Reexamination Certificate

active

08075902

ABSTRACT:
New devices and methods for diagnosis and compositions and methods for treatment of cancers use combinations of antimicrobial agents and agents that can reverse dormancy and hibernation pathways. We unexpectedly found that surprisingly low doses of anti-hibernation compounds can substantially inhibit cancer cell growth in vitro and can successfully treat cancers, including metastatic cancer. We also unexpectedly found that antimicrobial agents and anti-HDS compounds together can increase the degree of inhibition of cancer cell growth in a synergistic fashion. We conclude that combination therapy with antimicrobial agents and anti-HDS compounds can be effective in treating human patients with cancer.

REFERENCES:
patent: 2003/0228628 (2003-12-01), Powell

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Diagnosis and treatment of cancer related to human dormancy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnosis and treatment of cancer related to human dormancy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of cancer related to human dormancy will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4316081

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.